Craft

ASLAN Pharmaceuticals

Stock Price

$0.5

2024-04-12

Market Capitalization

$11.3 M

2024-04-12

ASLAN Pharmaceuticals Summary

Company Summary

Overview
ASLAN Pharmaceuticals is a clinical-stage oncology-focused biotechnology company developing novel therapeutics for global markets. The Company targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe.
Type
Public
Status
Active
HQ
SG | view all locations
Website
http://aslanpharma.com/
Cybersecurity rating
Sectors

Key People

  • Carl Firth

    Carl Firth, Chief Executive Officer

  • Stephen Doyle

    Stephen Doyle, Chief Business Officer

  • Kenneth Kobayashi

    Kenneth Kobayashi, Chief Medical Officer

    • Ben Goodger

      Ben Goodger, General Counsel

      LocationsView all

      4 locations detected

      • Collingwood, Victoria

        Australia

        58 Gipps St

      • Shanghai Shi

        China

        83 Wanhangdu Rd, Jingan Qu

      • Taipei City

        Taiwan

      ASLAN Pharmaceuticals Financials

      Summary Financials

      Net income (Q3, 2023)
      ($9.7M)
      Cash (Q3, 2023)
      $40.8M
      EBIT (Q3, 2023)
      ($8.5M)
      Enterprise value
      $8.3M

      Footer menu